Skip to search formSkip to main contentSkip to account menu

eteplirsen

Known as: (P-deoxy-P-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a?5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA 
National Institutes of Health

Related topics

Related topics

5 relations
2 ML eteplirsen 50 MG/ML InjectionAntisense Oligonucleotides

Narrower (2)

AVI-4658Exondys

Broader (1)

Morpholinos

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Gene-edited cows, rogue clinics, speedier drug approvals: the challenges facing Trump's FDA chief
The agency's next leader will have an opportunity to reshape its approach to regulation. 
2015
2015
An Open-label, Multi-Center, 48-week study with concurrent untreated control arm to evaluate the efficacy and safety of Eteplirsen in Duchenne Muscular Dystrophy
Eteplirsen is designed to “skip” a part of the gene that makes dystrophin called exon 51. For people who have changes, called… 
2015
2015
A Duchenne muszkuláris disztrófia (DMD) új farmakoterápiás lehetőségei: eteplirsen, drisapersen és ataluren